Dr. Rossana Berardi MD
Consultant Medical Oncologist, UNIVERSITA' POLITECNICA DELLE MARCHE
Member of the Healthcare Council
Council Member Biography
Rossana Berardi, MD, is a Researcher and Lecturer - Consultant Medical Oncologist in the Department of Medical Oncology at the Universita Politecnica delle Marche, Italy, since November 2005. She is involved in clinical research and GCP trials on the treatment of solid tumors in particular on gastrointestinal cancer and on NSCLC, and also in the clinical activities of the department. Dr. Berardi has been awarded many grants and prizes such as ASCO Travel Award in 2000 and an ASCO Merit Award in 2001. She has authored many scientific publications and several presentations at national and international meetings. Dr. Berardi was a Research Fellow in the Department of Oncology at Middlesex Hospital, University College London Hospitals. (This is me - Update Profile)
Employment History
- 2005 - Unspecified
- Consultant Medical Oncologist, UNIVERSITA' POLITECNICA DELLE MARCHE
- 2000 - Unspecified
- Lecturer, UNIVERSITA' POLITECNICA DELLE MARCHE
- 1999 - 1999
- Research Fellow, UNIVERSITY COLLEGE LONDON
GLG NewsSM Analyses by Rossana Berardi(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Cost will be the tricky point...
August 22, 2009
IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com
I believe that, considering the other available agents, gefitinib could be prescribed to up to 1/3 of NSCLC patients...
-
July 2, 2009
IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com
The approval of Iressa in NSCLC, opens the way to another therapeutic option in advanced NSCLC.
-
Iressa: will it be a new therapeutic option or will it replace another existing option?
May 4, 2009
IRESSA (Gefitinib) Recommended for Approval for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com
The recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMEA recommending to grant a marketing authorisation for Iressa in NSCLC, opens the way to another therapeutic option in advanced NSCLC.
-
Another good result for Roche.
March 23, 2009
UPDATE 1-Roche's Herceptin prolongs stomach cancer survival | www.reuters.com
The results from ToGA, a large international phase III trial, showed the benefit of herceptin plus chemotherapy vs chemotherapy alone as the first therapy for patients with advanced unresectable gastric cancer.
-
A Novel Option for Management of Malignant Ascites.
March 23, 2009
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE: SUMMARY OF POSITIVE OPINION FOR REMOVAB | www.emea.europa.eu
Catumaxomab is a trifunctional monoclonal antibody with 2 antigen-recognition sites: one for human EpCAM, a cell surface antigen expressed by a variety of epithelial tumor cells, and one for human CD3, a T-cell surface antigen. In addition, another region of the antibody binds to receptors that are expressed on other cells of the immune system.
Leading institutions connect with Rossana Berardi through GLG
GLG Study Groups with Rossana Berardi(?)
| Study Group Name | No. Members |
|---|---|
| Oncologists (EU) | 761 |
| Oncologists (Germany, France, Italy) | 343 |
| Physicians who Prescribe Opioids | 315 |
| Council Members who Treat Colon/Colorectal Cancer | 214 |
| Physicians who Treat Liver Cancer | 126 |
GLG Live Meetings with Rossana Berardi(?)
Rossana Berardi has not participated in any GLG Live Meetings.